Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

在诺和诺德（Novo Nordisk）宣布下调业绩增速指引，礼来公司（Eli Lilly and Company）公布产品替尔泊肽（Tirzepatide）的心血管保护作用非劣效于度拉糖肽（Dulaglutide）之后，8月1日，博瑞医药宣布将旗下明星产品BGM0504授权给华润三九，累计的研发投入里程碑付款最高为2.8亿元。 2.8亿元让这起商业授权快速获得了关注。累计里程碑付款代表了某一款产品 ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

An older woman with dementia and type 2 diabetes was started on semaglutide and subsequently developed severe psychological and physical symptoms, including apathy, significant weight loss and ...

A Phase III, international, randomized clinical trial assessed the safety and efficacy of canagliflozin for the treatment of ...

Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...